Who are oxaliplatin , fluorouracil, and leucovorin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, FLOX, Fluorouracil Injection, Pemetrexed + oral folinic acid rescue.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oxaliplatin-fluorouracil-and-leucovorin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

oxaliplatin , fluorouracil, and leucovorin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

oxaliplatin , fluorouracil, and leucovorin (oxaliplatin , fluorouracil, and leucovorin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Platinum-based chemotherapeutic agent and thymidylate synthase inhibitor. Area: Oncology.

phase 3 Platinum-based chemotherapeutic agent and thymidylate synthase inhibitor Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

oxaliplatin , fluorouracil, and leucovorin (oxaliplatin , fluorouracil, and leucovorin) — Sun Yat-sen University. Oxaliplatin, fluorouracil, and leucovorin work together to inhibit thymidylate synthase and DNA synthesis, leading to cell death in rapidly dividing cancer cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
oxaliplatin , fluorouracil, and leucovorin TARGET	oxaliplatin , fluorouracil, and leucovorin	Sun Yat-sen University	phase 3	Platinum-based chemotherapeutic agent and thymidylate synthase inhibitor	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
FLOX	FLOX	Hospira	marketed		Thymidylate synthase, Thymidylate synthase
Fluorouracil Injection	Fluorouracil Injection	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	marketed	Antimetabolite	Thymidylate synthase
Pemetrexed + oral folinic acid rescue	Pemetrexed + oral folinic acid rescue	Radboud University Medical Center	marketed	Antifolate antimetabolite	Thymidylate synthase, dihydrofolate reductase, glycinamide ribonucleotide formyltransferase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Platinum-based chemotherapeutic agent and thymidylate synthase inhibitor class)

Asan Medical Center · 1 drug in this class
Sun Yat-sen University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). oxaliplatin , fluorouracil, and leucovorin — Competitive Intelligence Brief. https://druglandscape.com/ci/oxaliplatin-fluorouracil-and-leucovorin. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab